ClinicalTrials.gg

Bulbo-Spinal Atrophy, X-Linked clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 57 studies for Bulbo-Spinal Atrophy, X-Linked across more than 10 countries. 11 are recruiting or about to start. 22 of them are mainly about Bulbo-Spinal Atrophy, X-Linked (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
25
Recruiting
11
Terminated
8
Active, not recruiting
6
Status unknown
4
Withdrawn
2

Phase

Phase 2
23
Phase 1
15
Phase 3
8
Phase 4
2

Where

United States
29
Italy
12
United Kingdom
9
France
8
Japan
8
China
7

Who develops what

Add Bulbo-Spinal Atrophy, X-Linked to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 4 companies, 1 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare AstraZeneca, Bristol-Myers Squibb and Novartis here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
enzalutamideRecent, repeated
Evidence
  • NCT07723248 · ORIC Pharmaceuticals · Phase 3 · live · comparator · “Enzalutamide” · registered Jun 2026
  • NCT06764485 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Enzalutamide” · registered Dec 2024
  • NCT03437941 · Corcept Therapeutics · Phase 2 · background · “Enzalutamide” · registered Jan 2018
Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized22 studies
DocetaxelRecent, repeated
Evidence
  • NCT07723248 · ORIC Pharmaceuticals · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
  • NCT06764485 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Docetaxel” · registered Dec 2024
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized22 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 12 Sept 2027 est.dezandrodeg · Bristol-Myers Squibb · Phase 3 registry mapping onlyvs enzalutamidevs Docetaxelvs Abiraterone AcetateNCT06764485 A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — primary endpoint: Radiographic progression-free survival (rPFS) by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (soft tissue) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteria · 960 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Bulbo-Spinal Atrophy, X-Linked studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antiandrogens 2 open

Coming up

5studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5, phase 3 first

Who these studies take

Of the 11 Bulbo-Spinal Atrophy, X-Linked studies recruiting now, 5 (45%) set no upper age limit and 2 (18%) stop at 75 or younger. 3 (27%) take children under 18. 1 (9%) are for women only and 3 (27%) for men only; 2 (18%) take healthy volunteers.

Recruiting studies that take each age, of 11
AgeWomenMen
103 (27%)3 (27%)
187 (64%)9 (82%)
308 (73%)10 (91%)
408 (73%)10 (91%)
508 (73%)10 (91%)
657 (64%)9 (82%)
757 (64%)9 (82%)
855 (45%)7 (64%)

Across all 57 studies, recruiting or not: 16% stop at 75 or younger and 9% at 65; 16% take children; 12% are for women only and 54% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 57. Browse all 57 → or search them.